1-[2-(4-bromophenyl)-2-chloroethyl]-N-(2-chlorobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | 1443752-54-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: 1-[2-(4-bromophenyl)-2-chloroethyl]-N-(2-chlorobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
• 英文别名: 1-[2-(4-bromophenyl)-2-chloroethyl]-N-[(2-chlorophenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-amine
• CAS: 1443752-54-2
• 化学式: C₂₀H₁₆BrCl₂N₅
• 分子量: 477.191
• InChiKey: PYGLWXFBTJNWSQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-[2-(4-bromophenyl)-2-chloroethyl]-N-(2-chlorobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 在 碳酸氢钠 作用下， 以 二氯甲烷 为溶剂， 反应 19.0h， 生成 2-(4-methylpiperazin-1-yl)ethyl 2-chlorobenzyl-1-(2-(4-bromophenyl)-2-chloroethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylcarbamate
  参考文献：
  名称：

  吡唑并[3,4- d ]嘧啶的前药：从文库合成到原位成胶质母细胞瘤模型中潜在抗癌药的评价

  摘要：

  吡唑并[3,4- d ]嘧啶是有效的蛋白激酶抑制剂，具有有希望的抗肿瘤活性，但水溶性较差，因此值得进一步优化。在这里，我们提出了一锅两步程序，用于合成一组具有较高水溶性和增强的药代动力学和治疗特性的吡唑并[3,4- d ]嘧啶前药（1a - 8a和9a - e）。ADME研究表明，最有前途的前药具有更好的水溶性，在人和鼠血清中具有良好的水解作用，并且相对于母体药物而言，其跨细胞膜的能力增强，这说明了它们在体外24小时的性能更好对人胶质母细胞瘤U87细胞系的细胞毒性。最后，还对体内的4–4a药物/前药进行了评估，揭示了前药具有良好疗效的有利的药代动力学特征。事实证明，前药方法的应用是提高母体药物水溶性的成功策略，对它们的生物学功效也产生了积极影响。

  DOI：

  10.1021/acs.jmedchem.7b00637
• 作为产物：
  描述：

  1-(2-(4-bromophenyl)-2-chloroethyl)-4-chloro-1H-pyrazolo[3,4-d]pyrimidine 、 邻氯苯甲胺 以 甲苯 为溶剂， 以39%的产率得到1-[2-(4-bromophenyl)-2-chloroethyl]-N-(2-chlorobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of Pyrazolo[3,4-d]pyrimidines Active in Vivo on the Bcr-Abl T315I Mutant

  摘要：

  Starting from our in-house library of pyrazolo, [3,4-d]pyrimidines, a cross-docking simulation was conducted, on Bcr-Abl T315I mutant. Among the selected, compounds; (2a-e), the 4-bromo derivative 2b showed the best activity against the Bcr-Abl T315I mutant. Deeper computational studies highlighted the importance of the bromine atom in the para position of the NI side chain phenyl,ring for the interaction with the T315I mutant. A series of 4;bromo derivatives was thin synthesized and biologically evaluated.: Compound 2j showed a good balance of different ADME properties, high activity in cell-free assays, and a submicromolar potency against T315I Bcr-Abl expressing cells. In addition, it was converted into a water-soluble formulation by liposome encapsulation, preserving a good activity on leukemic T315I cells and avoiding the use of DMSO as solubilizing agent. In vivo studies on mice inoculated with 32D-T315I cells and treated with 2j showed a more than 50% reduction in tumor volumes.

  DOI：

  10.1021/jm400233w

文献信息

• Design, Synthesis, and Biological Evaluation of Pyrazolo[3,4-<i>d</i>]pyrimidines Active in Vivo on the Bcr-Abl T315I Mutant
  作者：Marco Radi、Cristina Tintori、Francesca Musumeci、Chiara Brullo、Claudio Zamperini、Elena Dreassi、Anna Lucia Fallacara、Giulia Vignaroli、Emmanuele Crespan、Samantha Zanoli、Ilaria Laurenzana、Irene Filippi、Giovanni Maga、Silvia Schenone、Adriano Angelucci、Maurizio Botta

  DOI：10.1021/jm400233w

  日期：2013.7.11

  Starting from our in-house library of pyrazolo, [3,4-d]pyrimidines, a cross-docking simulation was conducted, on Bcr-Abl T315I mutant. Among the selected, compounds; (2a-e), the 4-bromo derivative 2b showed the best activity against the Bcr-Abl T315I mutant. Deeper computational studies highlighted the importance of the bromine atom in the para position of the NI side chain phenyl,ring for the interaction with the T315I mutant. A series of 4;bromo derivatives was thin synthesized and biologically evaluated.: Compound 2j showed a good balance of different ADME properties, high activity in cell-free assays, and a submicromolar potency against T315I Bcr-Abl expressing cells. In addition, it was converted into a water-soluble formulation by liposome encapsulation, preserving a good activity on leukemic T315I cells and avoiding the use of DMSO as solubilizing agent. In vivo studies on mice inoculated with 32D-T315I cells and treated with 2j showed a more than 50% reduction in tumor volumes.
• Prodrugs of Pyrazolo[3,4-<i>d</i>]pyrimidines: From Library Synthesis to Evaluation as Potential Anticancer Agents in an Orthotopic Glioblastoma Model
  作者：Giulia Vignaroli、Giulia Iovenitti、Claudio Zamperini、Federica Coniglio、Pierpaolo Calandro、Alessio Molinari、Anna Lucia Fallacara、Andrea Sartucci、Alessia Calgani、David Colecchia、Andrea Mancini、Claudio Festuccia、Elena Dreassi、Massimo Valoti、Francesca Musumeci、Mario Chiariello、Adriano Angelucci、Maurizio Botta、Silvia Schenone

  DOI：10.1021/acs.jmedchem.7b00637

  日期：2017.7.27

  Pyrazolo[3,4-d]pyrimidines are potent protein kinase inhibitors with promising antitumor activity but suboptimal aqueous solubility, consequently worth being further optimized. Herein, we present the one-pot two-step procedure for the synthesis of a set of pyrazolo[3,4-d]pyrimidine prodrugs (1a−8a and 9a−e) with higher aqueous solubility and enhanced pharmacokinetic and therapeutic properties. ADME

  吡唑并[3,4- d ]嘧啶是有效的蛋白激酶抑制剂，具有有希望的抗肿瘤活性，但水溶性较差，因此值得进一步优化。在这里，我们提出了一锅两步程序，用于合成一组具有较高水溶性和增强的药代动力学和治疗特性的吡唑并[3,4- d ]嘧啶前药（1a - 8a和9a - e）。ADME研究表明，最有前途的前药具有更好的水溶性，在人和鼠血清中具有良好的水解作用，并且相对于母体药物而言，其跨细胞膜的能力增强，这说明了它们在体外24小时的性能更好对人胶质母细胞瘤U87细胞系的细胞毒性。最后，还对体内的4–4a药物/前药进行了评估，揭示了前药具有良好疗效的有利的药代动力学特征。事实证明，前药方法的应用是提高母体药物水溶性的成功策略，对它们的生物学功效也产生了积极影响。